Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Protara Therapeutics, Inc. Director's Dealing 2020

Jan 13, 2020

34057_dirs_2020-01-13_2315a6ee-dbcb-4b73-b5e3-832167322a0e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ArTara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-01-09

Reporting Person: GARCEAU ROGER (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-01-10 Common Stock A 33000 $0.00 Acquired 33000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-01-09 Stock Option (Right to Buy) $9.18 A 12399 Acquired 2028-12-31 Common Stock (12399) Direct
2020-01-09 Stock Option (Right to Buy) $9.18 A 10491 Acquired 2029-04-28 Common Stock (10491) Direct

Footnotes

F1: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 3/24th of the shares were vested upon grant and 1/24th of the shares vest monthly thereafter, beginning on February 10, 2020. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full.

F2: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer.

F3: 1/48th of the shares subject to the option shall vest monthly thereafter for so long as the Reporting Person provides continuous service to the Issuer.

F4: Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share.

F5: 1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer.

F6: Received in the Merger in exchange for a stock option to acquire 55,000 shares of ArTara Sub common stock for $1.75 per share.